PTC Therapeutics traded at $66.06 this Friday September 11th, decreasing $1.31 or 1.94 percent since the previous trading session. Looking back, over the last four weeks, PTC Therapeutics lost 9.06 percent. Over the last 12 months, its price rose by 8.14 percent. Looking ahead, we forecast PTC Therapeutics to be priced at 64.65 by the end of this quarter and at 60.58 in one year, according to Trading Economics global macro models projections and analysts expectations.
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).